Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial

(2023) Athena Philis-Tsimikas et al.   Lancet Diabetes & Endocrinology

Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes

(2022) Athena Philis‐Tsimikas et al.   DIABETES OBESITY & METABOLISM

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

(2022) Nuha A. ElSayed et al.   DIABETES CARE

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

(2022) Tadej Battelino et al.   Lancet Diabetes & Endocrinology

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

(2021) Harpreet S. Bajaj et al.   DIABETES CARE

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100

(2021) Ildiko Lingvay et al.   DIABETES CARE

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing

(2021) Erica Nishimura et al.   BMJ Open Diabetes Research & Care

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

(2020) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

(2019) Simon R. Heller et al.   DIABETES CARE

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review

(2018) Jennifer Okemah et al.   ADVANCES IN THERAPY

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

(2017) Carol Wysham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1

(2016)   DIABETES CARE

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes

(2016) Lisa Elliott et al.   Diabetes Therapy

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes

(2016) Lisa Elliott et al.   Diabetes Therapy

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Effect of Tight Blood Glucose Control Versus Conventional Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

(2011) Anna Maria Buehler et al.   Cardiovascular Therapeutics

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

(2011) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Barriers to Insulin Initiation: The Translating Research Into Action for Diabetes Insulin Starts Project

(2010) A. J. Karter et al.   DIABETES CARE